Pomalidomide-PEG2-NH2 dihydrochloride

Background Introduction

Pomalidomide-PEG2-NH2 dihydrochloride is a specialized E3 ligase ligand-linker conjugate widely used in the design of PROTACs (Proteolysis Targeting Chimeras). As a derivative of pomalidomide—an immunomodulatory drug and a well-characterized cereblon (CRBN) E3 ligase ligand—this molecule features a PEG2 linker ending with a free amine group, enhancing its solubility and enabling straightforward conjugation to a broad range of target protein ligands. This versatile building block supports researchers in drug discovery and targeted protein degradation studies.

Mechanism

The mechanism of Pomalidomide-PEG2-NH2 dihydrochloride centers on the recruitment of the E3 ubiquitin ligase complex via its pomalidomide moiety, which binds selectively to cereblon. When incorporated into a PROTAC molecule, the PEG2 linker provides a flexible, hydrophilic spacer, improving drug-like properties and allowing optimal spatial orientation between the E3 ligase and the target protein. The NH2 terminal group serves as a conjugation site for coupling with ligands of various protein targets. In a cellular environment, the complete PROTAC induces proximity between cereblon and the target protein, leading to ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Pomalidomide-PEG2-NH2 dihydrochloride is primarily utilized in the synthesis of custom PROTACs for targeted protein degradation research. Its modular design allows medicinal chemists and chemical biologists to attach diverse warheads for the selective degradation of disease-relevant proteins. Common applications include preclinical studies in oncology, neurodegeneration, and immunology, where targeted protein knockdown can elucidate biological functions or validate new drug targets. This conjugate accelerates the development of next-generation therapeutics and chemical probes for advanced drug discovery pipelines.

Pomalidomide-PEG2-NH2 dihydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by linking E3 ligases to target proteins. This molecule is crucial for enhancing the specificity and efficacy of protein degradation, enabling detailed exploration in subsequent sections on the linker, ligand, and target protein ligand selection.

Linker: The linker in this molecule is a PEG2, which is characterized by its moderate length and flexible nature, allowing it to traverse molecular spaces effectively. Its non-cleavable design ensures stability and sustained interaction between the ligand and target protein, enhancing the conjugate's overall efficacy.

Ligand: The ligand component, pomalidomide, is a thalidomide derivative known for its ability to recruit cereblon, an E3 ubiquitin ligase. This structural feature is crucial for the selective degradation of target proteins, making it a valuable tool in protein homeostasis research.

Reactive Site: The reactive site of this molecule is the amino group (-NH2) at the terminus of the PEG2 linker. It is designed to couple with target protein ligands through amide bond formation or other nucleophilic substitution reactions, facilitating the formation of stable PROTACs.

Recommended Target Protein Ligand: A compatible warhead for this molecule would be an electrophilic group capable of forming a covalent bond with the amino group of the PEG2 linker. This configuration is advantageous for developing selective and potent PROTACs, enabling the targeted degradation of proteins involved in disease pathways, thereby offering new avenues for therapeutic research.